

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS  
PRICING ANTITRUST LITIGATION

MDL No. 2724  
Case No. 2:16-MD-2724

THIS DOCUMENT RELATES TO:  
  
*Direct Purchaser Plaintiffs' Actions*

HON. CYNTHIA M. RUFÉ

**NOTICE OF FILING OF OPT-OUT REPORT FOR  
DPPS' SANDOZ SETTLEMENT**

Pursuant to Paragraph 20 of this Court's June 26, 2024 Order granting preliminary approval to Direct Purchaser Plaintiffs' ("DPPs") Sandoz Settlement [MDL Doc. No. 3021], DPPs hereby provide notice of filing the attached Declaration of Eric J. Miller Regarding (A) Dissemination of the Notice and (B) Report on Request for Exclusion and Objections, If Any, Received to Date for DPPs' Sandoz Settlement.

Dated: October 29, 2024

Respectfully submitted,



Dianne M. Nast  
NASTLAW LLC  
1101 Market Street, Suite 2801  
Philadelphia, Pennsylvania 19107  
(215) 923-9300  
dnast@nastlaw.com

*Lead and Liaison Counsel  
for Direct Purchaser Plaintiffs*

David F. Sorensen  
BERGER MONTAGUE PC  
1818 Market Street, Suite 3600  
Philadelphia, Pennsylvania 19103  
(215) 875-3000  
dsorensen@bm.net

Thomas M. Sobol  
HAGENS BERMAN SOBOL SHAPIRO LLP  
1 Faneuil Hall Sq., 5th Floor  
Boston, Massachusetts 02109  
(617) 482-3700  
tom@hbsslaw.com

Robert N. Kaplan  
KAPLAN FOX & KILSHEIMER LLP  
800 Third Avenue, 38th Floor  
New York, New York 10022  
(212) 687-1980  
rkaplan@kaplanfox.com

Linda P. Nussbaum  
NUSSBAUM LAW GROUP, PC  
1133 Avenue of the Americas, 31st Floor  
New York, New York 10036  
(917) 438-9189  
lnussbaum@nussbaumpc.com

Michael L. Roberts  
ROBERTS LAW FIRM P.A.  
1920 McKinney Ave., Suite 700  
Dallas, Texas 75201  
(501) 821-5575  
mikeroberts@robertslawfirm.us

*Direct Purchaser Plaintiffs' Steering Committee*

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS  
PRICING ANTITRUST LITIGATION

MDL No. 2724  
Case No. 2:16-MD-2724

THIS DOCUMENT RELATES TO:

HON. CYNTHIA M. RUFÉ

*Direct Purchaser Plaintiffs' Actions*

**DECLARATION OF ERIC J. MILLER REGARDING  
(A) DISSEMINATION OF THE NOTICE AND (B) REPORT ON REQUESTS FOR  
EXCLUSION AND OBJECTIONS, IF ANY, RECEIVED TO DATE FOR  
DPPS' SANDOZ SETTLEMENT**

I, Eric J. Miller, hereby declare and state as follows:

1. I am a Senior Vice President with A.B. Data, Ltd. ("A.B. Data"). I am fully familiar with the facts contained herein based upon my personal knowledge, and if called as a witness, could and would testify competently thereto. I submit this declaration at the request of Settlement Class Counsel in connection with the above-captioned action (the "Action").

2. A.B. Data was appointed by the Court in its Sandoz Preliminary Approval Order dated June 26, 2024 to serve as the claims administrator for the direct purchaser class settlement with Sandoz. MDL Doc. No. 3021 ("Preliminary Approval Order"). A.B. Data's duties in this case include administering the distribution of notice of the settlement to class members. I am submitting this declaration to advise the Court of A.B. Data's activities concerning distribution of notice and the results.

**Direct Mail Notice**

3. A.B. Data obtained from Settlement Class Counsel a listing of 759 potential Settlement Class members developed from a number of sources, including transactional data produced by the defendants in discovery.

4. Settlement Class Counsel performed research to locate mailing addresses for these potential Settlement Class members. Where a potential Settlement Class member had multiple locations, each of the addresses was captured and included in the mailing database. In addition, A.B. Data supplemented the list with additional mailing addresses through review of A.B. Data's own records from other direct purchaser pharmaceutical appointments and further independent research.

5. As a result of these efforts, A.B. Data obtained the identity and office addresses of 748 potential Settlement Class members and a total of 1,343 mailing addresses for the 748 entities. A.B. Data and Settlement Class Counsel were not able to locate a mailing address for the remaining 11 potential Settlement Class members because the potential Settlement Class members were no longer in business or the name of the entity was incomplete so the actual entity could not be located.

6. On July 10, 2024, A.B. Data arranged for the mailing of the Long Form Notice (the "Notice") to all 748 potential Settlement Class members. The Notice was also mailed to the additional addresses for certain Settlement Class members. On the same day, A.B. Data posted the Notice on [www.GenericDrugsDirectPurchaserSettlement.com](http://www.GenericDrugsDirectPurchaserSettlement.com), the website created for this litigation. A copy of the Notice is attached hereto as **Exhibit A**.

7. In sum, A.B. Data caused 1,343 Notices to be mailed to potential Settlement Class members. If all mailings to a potential Settlement Class member were returned as undeliverable as addressed by the United States Postal Service, A.B. Data performed additional research to locate an updated address or determine if the potential Settlement Class member was no longer in existence. When A.B. Data was able to locate an updated address, A.B. Data promptly remailed the Notice to the updated address.

### **Media Notice**

8. To supplement direct notice efforts, beginning on July 10, 2024, A.B. Data caused digital banner ads to appear on The Pink Sheet website for a period of 30 days. The Pink Sheet reaches over 3,000 of the world's leading pharmaceutical, contract research organizations (CROs), medical technology, biotechnology and healthcare service providers, including the top 50 global pharma and top 10 CROs. These ads appeared on both desktop and mobile formats. 99,991 impressions have been delivered through the conclusion of the media notice on August 9, 2024. A sample of the digital banner and newsfeed ads are attached as **Exhibit B**.

9. A.B. Data also caused the Short Form Notice to be published in *The Wall Street Journal* on July 10, 2024. A copy is attached hereto as **Exhibit C**.

### **News Media**

10. On July 10, 2024, A.B. Data disseminated a news release via Business Wire to announce the Settlement. This news release distributed via Business Wire went to the news desks of approximately 10,000 newsrooms, including those of print, broadcast, and digital websites across the United States. A copy of the news release is attached as **Exhibit D**.

### **Website and Telephone**

11. To assist potential Settlement Class members in understanding the terms of the Settlement and their rights, and consistent with the earlier Settlements, A.B. Data utilized a case-specific toll-free telephone number (877-315-0583), email address (info@GenericDrugsDirectPurchaserSettlement.com), and a case-specific website (www.GenericDrugsDirectPurchaserSettlement.com).

12. On July 10, 2024, A.B. Data updated the case-specific toll-free telephone number to include an interactive voice response ("IVR") system which provided summary

information to frequently asked questions specific to the Sandoz Settlement. This also provided callers the opportunity to speak with a live customer support representative. In addition, A.B. Data has received emails to the email address established for this matter.

13. On July 10, 2024, A.B. Data updated the case-specific website, [www.GenericDrugsDirectPurchaserSettlement.com](http://www.GenericDrugsDirectPurchaserSettlement.com) to include information about the Sandoz Settlement. The website address appeared on the Notice and the newswire. The website includes case-specific information, including relevant deadlines and downloadable versions of the Notice, Settlement Agreements, Preliminary Approval Order, and other relevant documents. To date, the website has had 2,304 visitors.

14. On September 23, 2024, Settlement Class Counsel filed Direct Purchaser Plaintiffs' Motion for an Order Granting: (1) An Award of Attorneys' Fees; (2) Reimbursement of Expenses; and (3) Payment of Service Awards (MDL Doc. No. 3102). Promptly thereafter, A.B. Data posted this filing to the case-specific website.

#### **Requests for Exclusion and Objections**

15. Pursuant to the Court's Preliminary Approval Order, any Settlement Class member requesting exclusion from the Sandoz Settlement Class was required to postmark such a request on or before October 8, 2024.

16. As of the date of this Declaration, A.B. Data has received copies of nine (9) timely requests for exclusion on behalf of 404 entities. Annexed hereto as **Exhibit E** is a list of the entities which have submitted timely requests for exclusion from the Settlements.

17. All but one of the requests for exclusion have come from counsel for certain Direct Action Plaintiffs that I understand have brought individual claims.

18. Many of the entities identified in these letters, however, do not appear to be direct purchasers based on Defendants' transactional data (only 40 of the 404 cumulative entities seeking exclusion were identified as potential Settlement Class Members based on Defendants' transactional data). Therefore, based on Defendants' transactional data, it appears that 717 of 759 potential members of the Settlement Classes have not requested exclusion.

19. Pursuant to the Court's Preliminary Approval Order, the postmark deadline for a Settlement Class member to object to the Sandoz Settlement was also October 8, 2024.

20. The Notice directs members of the Settlement Class to mail their objection to Clerk of the United States District Court for the Eastern District of Pennsylvania with copies to Settlement Class Counsel and Settling Defendants' Counsel.

21. As of the date of this Declaration, A.B. Data has not been notified of any objections.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on October 29, 2024



---

Eric J. Miller

# EXHIBIT A



IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

**If you purchased one or more of the Named Generic Drugs listed in Appendix A to this Notice directly from any of the pharmaceutical manufacturer Defendants or former Defendants (listed in Appendix B to this Notice) at any time from May 1, 2009 until December 31, 2019, you could get a payment from a class action settlement.**

*A federal court authorized this notice. This is not a solicitation from a lawyer.*

You were previously sent a notice about settlements with (1) Sun Pharmaceuticals Industries, Inc. (“Sun”), (2) Taro Pharmaceuticals U.S.A. Inc. (“Taro”), (3) Apotex Corp. (“Apotex”), (4) Breckenridge Pharmaceutical Inc. (“Breckenridge”), and (5) Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals Ltd. and Satish Mehta (“Heritage”). The purpose of this notice is to alert you of a proposed additional settlement in a Lawsuit brought by Direct Purchasers (“Settling Direct Purchaser Plaintiffs” or “DPPs”) of certain generic drugs (the “Named Generic Drugs”). The Lawsuit is a group of direct purchaser class actions coordinated under the civil docket *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 (E.D. Pa.). The Lawsuit claims that generic drug manufacturers violated antitrust laws, harming competition and causing Settlement Class Members to overpay for the Named Generic Drugs. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. No trial has been held.

- An additional settlement has been reached between the DPPs and Settling Defendants Sandoz Inc. and Fougera Pharmaceuticals Inc. Settling Defendants are alleged to have violated the antitrust laws relating to the sale of the Named Generic Drugs. The proposed settlement does not resolve any of the claims of the DPPs against the remaining Defendants. The Lawsuit against the remaining Defendants is ongoing. The Named Generic Drugs are listed in Appendix A, and the Current and Former Defendants are listed in Appendix B.
- The Court has certified a Settlement Class comprised of:

All persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Current or Former Defendants in the United States and its territories and

possessions, at any time during the period from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.

- The Court has preliminarily approved the proposed Settlement between the Settling Direct Purchaser Plaintiffs and the respective Settling Defendants. To resolve the DPPs' claims against Settling Defendants, the proposed Settlement will provide for a \$265,000,000.00 payment by Sandoz Inc. and Fougera Pharmaceuticals Inc. This payment will comprise the "Settlement Fund." The Settlement Fund may be reduced by up to \$31,800,000.00 (to \$233,200,000.00), or increased by a maximum of \$62,351,850.00 (to \$327,351,850.00) under certain circumstances, as explained in the Settlement Agreement. As discussed below, attorneys' fees, expenses and service awards may be deducted from these amounts, with Court approval.
- The Court has scheduled a hearing to decide whether to approve the Settlement, the plan for allocating the Settlement Fund to Settlement Class Members, any requests by the attorneys for reimbursement of expenses out of the Settlement Fund, payment of service awards to the Settling Plaintiffs, and any request by attorneys for payment of attorneys' fees, (the "Final Fairness Hearing"). The Final Fairness Hearing is scheduled for March 17, 2025, at 10:30 a.m. ET, before Judge Cynthia M. Rufe at the United States District Court for the Eastern District of Pennsylvania, Courtroom 12-A, 601 Market Street, Philadelphia, PA 19106.

**YOUR LEGAL RIGHTS ARE AFFECTED WHETHER YOU ACT OR DO NOT ACT,  
SO PLEASE READ THIS NOTICE CAREFULLY.**

<b>YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT</b>	
<b>WHEN YOU RECEIVE A CLAIM FORM, PROMPTLY COMPLETE AND RETURN IT</b>	<p>You do not need to do anything now to retain your right to stay in the Settlement Class and/or seek a share of the proposed Settlement. If the Court decides to give the proposed Settlement Final Approval and you are a Settlement Class Member, then you will need to complete, sign and return a Claim Form to obtain a share of the proposed Settlement.</p> <p>If you received a Notice in the mail, a Claim Form will be mailed to you at a later date.</p> <p>If you <u>did not</u> receive a Notice in the mail and you think you are a potential Settlement Class Member, please identify yourself by letter or email to the following address: <i>In re: Generic Pharmaceuticals Pricing Antitrust Litigation</i> – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217.</p> <p>Email: <a href="mailto:info@GenericDrugsDirectPurchaserSettlement.com">info@GenericDrugsDirectPurchaserSettlement.com</a>.</p> <p>You will be asked to provide information or data proving that you are a member of a Settlement Class. You also may be asked to provide data showing your eligible purchases.</p>
<b>EXCLUDE YOURSELF FROM THE SETTLEMENT CLASS</b>	<p>You may choose to exclude yourself, or “opt out,” from the Settlement Class. If you choose to exclude yourself from the Settlement, you will not be bound by any decision in this Lawsuit relating to the Settling Defendants. This is the only option that allows you to ever be part of any lawsuit (other than this Lawsuit) against the Settling Defendants relating to the legal claims against the Settling Defendants in this case.</p>
<b>STAY IN THE LAWSUIT BUT OBJECT TO THE SETTLEMENT</b>	<p>If you remain in the Settlement Class, you may object to all or any part of the proposed Settlement, and may write to the Court about why you do not like the proposed Settlement.</p>
<b>GET MORE INFORMATION</b>	<p>If you would like to obtain more information about the Lawsuit or the Settlement, you can send questions to the lawyers or Claims Administrator identified in this notice and/or ask to attend the hearing at which the Court will evaluate the proposed Settlement.</p>

*These rights and options – and the deadlines to exercise them – are explained in this notice.*

## TABLE OF CONTENTS

### WHAT THIS NOTICE CONTAINS

<b>BASIC INFORMATION .....</b>	<b>PAGE 5</b>
1. Why did I get this notice?	
2. What is this lawsuit about?	
3. What is a class action?	
4. Why is there a Settlement?	
<b>WHO IS IN THE SETTLEMENT CLASS AND SETTLEMENT.....</b>	<b>PAGE 6</b>
5. Am I part of the Settlement Class?	
6. Can I Request to be excluded from the Settlement Class?	
7. What happens if I do nothing?	
<b>THE SETTLEMENT'S BENEFITS .....</b>	<b>PAGE 8</b>
8. What does the Settlement provide?	
9. How can I get a payment from the Settlement?	
10. When would I get my payment and how much would it be?	
<b>THE LAWYERS REPRESENTING THE SETTLEMENT CLASS .....</b>	<b>PAGE 10</b>
11. Do I have a lawyer in this case?	
12. How will the lawyers be paid?	
<b>OBJECTING TO THE SETTLEMENT .....</b>	<b>PAGE 11</b>
13. How do I tell the Court that I don't like the Settlement?	
<b>THE COURT'S FAIRNESS HEARING .....</b>	<b>PAGE 12</b>
14. When will the Court decide whether to approve the Settlement?	
15. Do I have to attend the hearing?	
16. May I speak at the hearing?	
<b>GETTING MORE INFORMATION .....</b>	<b>PAGE 13</b>
17. How do I get more information?	

## BASIC INFORMATION

### 1. WHY DID I GET THIS NOTICE?

You received this notice because, according to available data and documents, you may have purchased one or more Named Generic Drugs directly from one or more generic manufacturer Defendants at some time from May 1, 2009 until December 31, 2019 and therefore you may be a member of the Settlement Class that was certified by the Court for purposes of the proposed Settlement. You may have received this Notice in error and so you should confirm from your own records that you purchased one or more Named Generic Drugs directly from one or more generic manufacturer Defendants at some time from May 1, 2009 to December 31, 2019.

### 2. WHAT IS THIS LAWSUIT ABOUT?

The Lawsuit is a group of proposed class actions coordinated under the docket *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724. DPPs' class action complaints are available at [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com). Judge Cynthia M. Rufe, of the United States District Court for the Eastern District of Pennsylvania (the "Court"), is overseeing the Lawsuit and the Settlement.

The Settling Direct Purchaser Plaintiffs allege that Defendants engaged in an unlawful scheme or schemes to fix, maintain and stabilize prices, rig bids, and engage in market and customer allocation of the Named Generic Drugs in violation of federal antitrust laws. DPPs allege that this harmed competition and caused Settlement Class Members to overpay for the Named Generic Drugs.

All Defendants, including the Settling Defendants, deny that any Settlement Class Member is entitled to damages or other relief. All Defendants, including the Settling Defendants, deny liability as to DPPs' claims. The Settlement between Settling Direct Purchaser Plaintiffs and the Settling Defendants is not an admission of wrongdoing by any Defendant, including the Settling Defendants.

Following investigation of relevant facts, substantial fact discovery, and following arms' length negotiations with the Settling Defendants, the Settling Direct Purchaser Plaintiffs, on behalf of the Settlement Class, entered into the Settlement with the Settling Defendants.

There has been no determination by the Court or a jury that the allegations against the Defendants or Settling Defendants have been proven or that, if proven, the conduct caused harm to any Settlement Class Members. No trial has been held or scheduled.

### 3. WHAT IS A CLASS ACTION?

In a class action, one or more people called "Class Representatives" (in this case, César Castillo, LLC, FWK Holdings, LLC, Rochester Drug Cooperative, Inc., and KPH Healthcare Services, Inc.) sue on behalf of others who have similar claims (collectively, the "DPPs" or the "Settling Direct Purchaser Plaintiffs").

The DPPs and the entities on whose behalf they have sued together constitute the "Settlement Class" or "Settlement Class Members." Their attorneys are called "Settlement Class Counsel."

The companies that have been sued are called the "Defendants." In this case the Current and Former Defendants are the 58 companies listed at the end of this Notice.

In a class action lawsuit, one court resolves the issues for all Class Members, except for those who exclude themselves (i.e., “opt out”) from the Class. The Court, by an order dated June 26, 2024, has determined that the lawsuit between DPPs and the Settling Defendants can proceed as a class action for purposes of settlement. Copies of the Court’s orders may be found at [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com).

Specifically, the Court has found that:

- The number of Settlement Class Members is so numerous that joining them all into one suit is impracticable.
- Members of the Settlement Class share common legal or factual issues relating to the claims in this case.
- The claims of the DPPs are typical of the claims of the rest of the Settlement Class.
- The DPPs and Settlement Class Counsel will fairly and adequately protect the interests of the Settlement Class.
- The common legal questions and facts predominate over questions affecting only individual members of the Settlement Class, and this Lawsuit will be more efficient than individual lawsuits.

#### 4. WHY IS THERE A SETTLEMENT?

The Court has not decided in favor of the Settling Direct Purchaser Plaintiffs or Settling Defendants. Instead, both sides have agreed to the Settlement. Settling Direct Purchaser Plaintiffs and the Settling Defendants were preparing to proceed with the litigation and eventually go to trial, but they have now agreed to the Settlement. By agreeing to the Settlement, the parties avoid the costs and uncertainty of additional discovery, motion practice, and an eventual trial, and if the Settlement is approved by the Court, Settlement Class Members will be eligible to receive a payment from the Settlement. The Settlement does not mean that any law was broken or that the Settling Defendants did anything wrong. The DPPs and Settlement Class Counsel believe that the proposed Settlement is fair, reasonable, and adequate and in the best interests of the Settlement Class.

### WHO IS IN THE SETTLEMENT CLASS AND SETTLEMENT

#### 5. AM I PART OF THE SETTLEMENT CLASS AND THE SETTLEMENT?

You are part of the Settlement Class if you are a person or entity in the United States and its territories that purchased one or more Named Generic Drugs directly from one or more Current or Former Defendants at any time from May 1, 2009 until December 31, 2019.

More specifically, on June 26, 2024, the Court certified the Settlement Class. The class definition is:

All persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Current or Former Defendants in the United States and its territories and possessions at any time during the period from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.

The Named Generic Drugs and Current and Former Defendants are listed at the end of this Notice.

If you are not sure whether you are included in the Settlement Class, you may call or write to the lawyers in this case at the telephone numbers or addresses listed in Question 11 below. If you wish to exclude yourself from the Settlement Class, please refer to Question 6.

#### 6. CAN I REQUEST TO BE EXCLUDED FROM THE SETTLEMENT CLASS?

Yes, the Court has set a deadline for requests for exclusion for October 8, 2024. To exclude yourself, you must send a letter via First-Class U.S. Mail saying you want to exclude yourself from the Direct Purchaser Lawsuit in *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724 (E.D. Pa.).

Mail the letter to: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217.

**Be sure to include your name, address, email address, telephone number, and your signature. Your letter requesting exclusion must be postmarked no later than October 8, 2024.**

If you exclude yourself from the Settlement Class, you will not be legally bound by anything that happens in the Lawsuit between DPPs and the Settling Defendants. This means that you may be able to sue (or continue to sue) the Settling Defendants in the future about the legal issues in this case. If you exclude yourself from the Settlement Class so that you can start or continue your own lawsuit against one or more of the Settling Defendants, you should talk to your own lawyer immediately because your claims will be subject to a statute of limitations, which means that your claims will expire if you do not take timely action. You need to contact your own lawyer about this issue.

If you do not exclude yourself from the Settlement Class, and you have a valid claim, you can share in the Settlement, but you will not be able to start a lawsuit, continue a lawsuit, or be part of any other lawsuit against the Settling Defendants arising from the claims released as part of this Settlement, including claims brought in the case between DPPs and the Settling Defendants. All of the Court's orders in the case between DPPs and the Settling Defendants will apply to you and legally bind you. You will also be bound by the proposed Settlement between DPPs and the Settling Defendants if the Court grants Final Approval to the proposed Settlement and enters final judgment in the case between DPPs and the Settling Defendants.

#### 7. WHAT HAPPENS IF I DO NOTHING?

If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and be eligible to participate in the Settlement as described in this notice, if the Settlement is approved. However, you will need to complete, sign, and return the claim forms (once they are sent to you) in order to obtain a payment. We do not know when the claim forms will be mailed. You should check [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com) for information regarding timing. The website will also have a blank claim form for downloading.

## THE SETTLEMENT'S BENEFITS

### 8. WHAT DOES THE SETTLEMENT PROVIDE?

The Settling Defendants have agreed to pay a total of \$265,000,000.00 in cash (which may be reduced to \$233,200,000.00 or increased to as much as \$327,351,850.00 under certain circumstances as explained in the Settlement) to an interest-bearing escrow account ("Settlement Fund") for the benefit of the Settlement Class. The Settlement Fund shall be held in escrow pending finality of the Settlement Agreement. The Settling Defendants have also agreed to provide substantial cooperation to the DPPs in the continued litigation against the remaining Defendants.

Settlement Class Counsel will apply to the Court no later than August 23, 2024 for reimbursement of past unreimbursed expenses and for future expenses not to exceed a total of \$2 million, and service awards to the four Settling Plaintiffs of \$20,000 each for their services to the Settlement Class. The Settlement also provides for payment of up to \$250,000 in total for the costs of administering the Settlement and making distributions from the fund. In addition, Settlement Class Counsel will ask the Court for payment of attorneys' fees. For purposes of the objection and opt-out deadline of October 8, 2024, Settlement Class Members should assume that Settlement Class Counsel will seek attorney's fees of up to one-third of the net Settlement Funds to date, after expenses and service awards have been deducted and including interest (and including the Settlement Funds from DPPs' prior Settlements). Settlement Class Members will have the opportunity to review, and object to, Settlement Class Counsel's motion for attorneys' fees after it is filed and before the Court rules. All motions for expenses, attorneys' fees, and service awards shall be posted on the settlement website: [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com).

If approved by the Court, the Settlement Fund, minus any court-awarded fees and expenses to Settlement Class Counsel, costs of settlement notice and administration, and service awards to Settling Plaintiffs ("Net Settlement Fund") will be distributed to the Settlement Class Members who return valid and timely Claim Forms. The distribution will be made on a *pro rata* basis, consistent with each Settlement Class Member's aggregate weighted share of total Settlement Class purchases of the Named Generic Drugs from Defendants. In the event that data from Defendants is not available to calculate a Settlement Class Member's *pro rata* share, such Settlement Class Member will be required to submit data showing its relevant direct purchases as requested by the Claims Administrator. As a general matter, a claimant's *pro rata* share will be based on data from Defendants, and claimants will not be permitted to submit their own purchase data to contest these figures. This is because of the time and expense that would be involved in analyzing such additional data (expenses that would be paid out of the Settlement Fund itself), and because transaction data from Defendants is considered reliable. More information about how Settlement Class Members' shares will be calculated is available in the Plan of Allocation on the settlement website: [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com).

In exchange, the litigation between the DPPs and the Settling Defendants will be dismissed with prejudice and Settling Defendants will be released by Settlement Class Members from all claims that have been brought or could have been brought concerning the subject matter of or acts, omissions, or other conduct alleged in Settling Direct Purchaser Plaintiffs' class action complaints available at [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com).

Non-Settling Defendants are **not** part of the proposed Settlement between the DPPs and the Settling Defendants. DPPs' Lawsuit against the Non-Settling Defendants is continuing.

The Settlement Agreement provides that it may be terminated if, for example, the Court does not approve the Settlement or if Settlement Class Members with aggregate purchases above a certain



amount opt out. If the Settlement Agreement is terminated, the Lawsuit will proceed against the Settling Defendants as if the settlement had not been reached.

The full text of the Settlement Agreement, including the release, is available at [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com). This notice is not meant to, and does not, alter the terms of the actual Settlement Agreement and associated release.

## 9. HOW CAN I GET A PAYMENT FROM THE SETTLEMENT?

If the Court grants Final Approval to the Settlement (*see* “The Court’s Fairness Hearing” below) and any resulting appeals are resolved, the Court will approve a Plan of Allocation to distribute the Settlement Fund.

**If you do not exclude yourself from the Settlement Class, you will need to submit a Claim Form to request your share of the Net Settlement Fund.**

- If you received this Notice in the mail, a Claim Form will be sent to you automatically and you do not need to do anything at this time to be eligible to receive a payment from the Settlement.
- If you did not receive this Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter or email to the following address: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217. Email: [info@GenericDrugsDirectPurchaserSettlement.com](mailto:info@GenericDrugsDirectPurchaserSettlement.com). You must also include proof that you purchased at least one of the Named Generic Drugs during the period May 1, 2009 to December 31, 2019 directly from a Current or Former Defendant. You may also be required to submit your purchase data showing all your eligible purchases. A copy of the Claim Form will also be available at [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com).

## 10. WHEN WOULD I GET MY PAYMENT AND HOW MUCH WOULD IT BE?

When you get your payment depends on several matters, including whether and when the Court grants Final Approval of the Settlement. The Net Settlement Fund will be allocated to Settlement Class Members as soon as possible after the Court grants Final Approval of the Settlement.

You will not be responsible for calculating the amount you may be entitled to receive. The Plan of Allocation provides that you will be paid on a *pro rata* basis in proportion to how much of the Named Generic Drugs you purchased directly from Current or Former Defendants from May 1, 2009 through December 31, 2019. Generally, those with more purchases will get a higher recovery. If less than 100% of the Settlement Class sends in claim forms, you could get a larger *pro rata* share. All Claimants who would receive less than a *pro rata* share of \$25 total from the Settlement will receive \$25 total from the Settlement.

If the proposed Settlement is given Final Approval, but there is an appeal of the Final Approval, the appeal could take several years to resolve. Any accrued interest on the Settlement Fund will be included, *pro rata*, in the amount paid to Settlement Class Members.

If you do decide to exclude yourself from the Settlement Class, which means that you are choosing not to be a part of the Settlement Class, then you will not receive a share the Settlement Fund.

## THE LAWYERS REPRESENTING THE CLASS

### 11. DO I HAVE A LAWYER IN THIS CASE?

The Court appointed the counsel listed below as Settlement Class Counsel:

<p>Dianne M. Nast, Esq. Joseph N. Roda, Esq. NASTLAW LLC 1101 Market Street, Suite 2801 Philadelphia, PA 19107 (215) 923-9300 dnast@nastlaw.com jnroda@nastlaw.com</p>	<p>David F. Sorensen, Esq. BERGER MONTAGUE PC 1818 Market Street, Suite 3600 Philadelphia, PA 19103 (215) 875-3000 dsorensen@bm.net</p>
<p>Robert N. Kaplan KAPLAN FOX &amp; KILSHEIMER LLP 800 Third Avenue, 38<sup>th</sup> Floor New York, NY 10022 (212) 687-1980 rkaplan@kaplanfox.com</p>	<p>Thomas M. Sobol, Esq. HAGENS BERMAN SOBOL SHAPIRO LLP 1 Faneuil Hall Square, 5th Floor Boston, MA 02109 (617) 482-3700 tom@hbsslaw.com</p>
<p>Linda P. Nussbaum NUSSBAUM LAW GROUP, PC 1133 Avenue of the Americas, 31st Floor New York, NY 10036 (917) 438-9189 lnussbaum@nussbaumpc.com</p>	<p>Michael L. Roberts ROBERTS LAW FIRM P.A. 1920 McKinney Ave., Suite 700 Dallas, TX 75201 (501) 821-5575 mikeroberts@robertslawfirm.us</p>

### 12. HOW WILL THE LAWYERS BE PAID?

The attorneys intend to ask for attorneys' fees of (1) up to one-third of this Settlement Fund and (2) the entirety of any funds set aside by Court Order for fee petitions from any of Direct Purchaser Plaintiffs' previous Settlements. Settlement Class Counsel will also ask now, as part of the Final Approval of this settlement, for an amount not to exceed a total of \$2 million for reimbursement of past and future expenses, including costs of administering this settlement, plus service awards in the amount of \$20,000 for each of the four named plaintiffs. If you decide not to exclude yourself from the Settlement Class, you will not have to pay these fees, costs, and expenses out of your own pocket. If the Court grants Settlement Class Counsel's requests, these amounts would be deducted from the Settlement Fund.

Any application by Settlement Class Counsel for reimbursement of expenses, service awards, and attorneys' fees will be filed with the Court and made available for download and/or viewing on or before November 22, 2024 on [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com), as well as at the office of the Clerk of the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106-1797, during normal business hours.

## OBJECTING TO THE SETTLEMENT

### 13. HOW DO I TELL THE COURT THAT I DON'T LIKE THE SETTLEMENT?

If you are a Settlement Class Member (and have not excluded yourself), you can object to all or any part of the proposed Settlement and/or the application for attorneys' fees, reimbursement of costs and expenses, and/or service awards to the Class Representatives. You can give reasons why you think the Court should not approve it. The Court will consider your views.

To object to the Settlement, you must send a letter via First-Class U.S. Mail saying that you object to the Settlement in the Direct Purchaser Lawsuit in *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.) with the following information:

- Your name, address, and phone number and the name, address, and phone number of your attorney, if you have one.
- Your signature
- Case name and number:

*In re Generic Pharmaceuticals Pricing Antitrust Litigation*  
Case No. 2:16-MD-02724

United States District Court for the Eastern District of Pennsylvania

- The specific reasons why you object to the settlement or any part of it.
- All documents or writings that you want the Court to consider.

Mail the objection to the Clerk of the United States District Court for the Eastern District of Pennsylvania (address below) with copies to the individuals and addresses listed below:

CLERK OF THE COURT	SETTLEMENT CLASS COUNSEL	SETTLING DEFENDANTS' COUNSEL
Clerk of Court, EDPA 601 Market Street Philadelphia, PA 19106	Dianne M. Nast Joseph N. Roda NastLaw LLC 1101 Market Street, Ste 2801 Philadelphia, PA 19107	Matthew Kent Alston & Bird LLP 1201 W Peachtree St. NE #4900 Atlanta, GA 30309

**Your objection must be postmarked on or before October 8, 2024.**

## THE COURT'S FAIRNESS HEARING

The Court will hold a hearing to decide whether to grant Final Approval to the Settlement and any requests for reimbursement of expenses, service awards, and application for attorneys' fees ("Fairness Hearing"). You may attend and, if you have not excluded yourself from the Settlement Class, you may ask to speak, but you do not have to.

### 14. WHEN WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENT?

The Court has scheduled a Fairness Hearing on March 17, 2025 at 10:30 a.m. Eastern time, at the United States District Court Eastern District of Pennsylvania, Courtroom 12-A, 601 Market Street, Philadelphia, PA 19106.

**The time and date of the Fairness Hearing may change without additional mailed notice. For updated information on the hearing, you may check [GenericDrugsDirectPurchaserSettlement.com](https://pcl.uscourts.gov), or the Court docket in this case, for a fee, through the Court's Public Access to Court Electronic Records (PACER) system at <https://pcl.uscourts.gov>.**

At the Fairness Hearing, the Court will consider whether the Settlement is fair, reasonable, and adequate. The Court may also consider the requests by Settlement Class Counsel for attorneys' fees, reimbursement of expenses, and payment of service awards. If there are objections, the Court will consider them at that time. After the hearing, the Court will decide whether to give Final Approval to the Settlement and the other requests. It is unknown how long these decisions will take.

Any judgment issued by the Court will be binding on the Settlement Class. The Settlement, if approved by the Court and once appeals, if any, are resolved, will release all claims in the class action against the Settling Defendants.

### 15. DO I HAVE TO ATTEND THE HEARING?

No. Settlement Class Counsel will answer any questions the Court may have. However, you are welcome to attend the hearing at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mailed your written objection on time, to the proper addresses, and it complies with the other requirements provided above, the Court will consider it. You also may pay your own lawyer to attend the hearing, but this is not necessary. Attendance is not necessary to receive your share of the Net Settlement Fund.

### 16. MAY I SPEAK AT THE HEARING?

You may ask the Court for permission to speak at the Fairness Hearing. To do so, you must send a letter via First-Class U.S. Mail saying that it is your "Notice of Intention to Appear in *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.)." Be sure to include your name, address, email address, telephone number, and your signature. Your Notice of Intention to Appear must be postmarked no later than October 8, 2024, and must be sent to the Clerk of the Court, to Settlement Class Counsel, and to Settling Defendants' Counsel at the addresses listed in Question 13 above.

You may not speak at the hearing for a particular Settlement if you excluded yourself as a Settlement Class Member or do not send a Notice of Intention to Appear.

## GETTING MORE INFORMATION

### 17. HOW DO I GET MORE INFORMATION?

If you have questions about this case or want additional information, you may call or write to the lawyers listed in the answer to Question 11 above, call 877-315-0583, or visit [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com). This notice is only a summary of the proposed Settlement and is qualified in its entirety by the terms of the Settlement Agreement. Copies of the Settlement Agreements are on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106. The Settlement Agreement is also available on the settlement website: [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com). You may also call the Claims Administrator at 877-315-0583 with questions.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK'S OFFICE TO  
INQUIRE ABOUT THE SETTLEMENT OR THE CLAIMS PROCESS

**APPENDIX A: NAMED GENERIC DRUGS**

Molecule Name	Form	Strength
(1)	(2)	(3)
1 ACETAZOLAMIDE	TABLET	125MG
1 ACETAZOLAMIDE	TABLET	250MG
1 ACETAZOLAMIDE ER	CAPSULE	500MG
2 ADAPALENE	CREAM	0.1%
2 ADAPALENE	GEL	0.1%
2 ADAPALENE	GEL	0.3%
3 ALBUTEROL	TABLET	2MG
3 ALBUTEROL	TABLET	4MG
4 ALCLOMETASONE DIPROPIONATE	CREAM	0.05%
4 ALCLOMETASONE DIPROPIONATE	OINTMENT	0.05%
5 ALLOPURINOL	TABLET	100MG
5 ALLOPURINOL	TABLET	300MG
6 AMANTADINE HCL	CAPSULE	100MG
7 AMILORIDE HCL/HCTZ	TABLET	5MG;50MG
8 AMITRIPTYLINE	TABLET	100MG
8 AMITRIPTYLINE	TABLET	10MG
8 AMITRIPTYLINE	TABLET	150MG
8 AMITRIPTYLINE	TABLET	25MG
8 AMITRIPTYLINE	TABLET	50MG
8 AMITRIPTYLINE	TABLET	75MG
9 AMMONIUM LACTATE	CREAM	12%
9 AMMONIUM LACTATE	LOTION	12%
10 AMOXICILLIN/CLAVULANATE	TABLET CHEWABLE	200MG;28.5MG
10 AMOXICILLIN/CLAVULANATE	TABLET CHEWABLE	400MG;57MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	10MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	20MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	30MG
11 AMPHETAMINE/DEXTROAMPHETAMINE (MAS) (ADDERALL)	TABLET	5MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	10MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	15MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	20MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	25MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	30MG
11 AMPHETAMINE/DEXTROAMPHETAMINE ER (MAS) (ADDERALL)	CAPSULE	5MG
12 ATENOLOL/CHLOROTHALIDONE	TABLET	100MG;25MG
12 ATENOLOL/CHLOROTHALIDONE	TABLET	50MG;25MG
13 ATROPINE SULFATE	SOLUTION	1%
14 BACLOFEN	TABLET	10MG
14 BACLOFEN	TABLET	20MG
15 BALSALAZIDE DISODIUM	CAPSULE	750MG
16 BENAZEPRIL HCTZ	TABLET	10MG;12.5MG
16 BENAZEPRIL HCTZ	TABLET	20MG;12.5MG
16 BENAZEPRIL HCTZ	TABLET	20MG;25MG
17 BETAMETHASONE DIPROPIONATE	CREAM	0.05%
17 BETAMETHASONE DIPROPIONATE	LOTION	0.05%
17 BETAMETHASONE DIPROPIONATE	OINTMENT	0.05%
18 BETAMETHASONE DIPROPIONATE AUGMENTED	LOTION	0.05%
19 BETAMETHASONE DIPROPIONATE/CLOTTRIMAZOLE	CREAM	0.05%;1%
19 BETAMETHASONE DIPROPIONATE/CLOTTRIMAZOLE	LOTION	0.05%;1%
20 BETAMETHASONE VALERATE	CREAM	0.1%
20 BETAMETHASONE VALERATE	LOTION	0.1%
20 BETAMETHASONE VALERATE	OINTMENT	0.1%
21 BETHANECHOL CHLORIDE	TABLET	10MG
21 BETHANECHOL CHLORIDE	TABLET	25MG
21 BETHANECHOL CHLORIDE	TABLET	50MG
21 BETHANECHOL CHLORIDE	TABLET	5MG
22 BROMOCRIPTINE MESYLATE	TABLET	2.5MG
23 BUDESONIDE	SOLUTION	0.25MG/2ML
23 BUDESONIDE	SOLUTION	0.5MG/2ML
23 BUDESONIDE	SOLUTION	1MG/2ML
23 BUDESONIDE DR	CAPSULE	3MG
24 BUSPIRONE HCL	TABLET	10MG
24 BUSPIRONE HCL	TABLET	15MG
24 BUSPIRONE HCL	TABLET	30MG
24 BUSPIRONE HCL	TABLET	5MG
24 BUSPIRONE HCL	TABLET	7.5MG
25 BUTORPHANOL TARTRATE	SPRAY	10MG/ML
26 CAPECITABINE	TABLET	150MG
26 CAPECITABINE	TABLET	500MG
27 CAPTOPRIL	TABLET	100MG
27 CAPTOPRIL	TABLET	12.5MG
27 CAPTOPRIL	TABLET	25MG
27 CAPTOPRIL	TABLET	50MG
28 CARBAMAZEPINE	TABLET	200MG
28 CARBAMAZEPINE	TABLET CHEWABLE	100MG
28 CARBAMAZEPINE ER	TABLET	100MG
28 CARBAMAZEPINE ER	TABLET	200MG
28 CARBAMAZEPINE ER	TABLET	400MG
29 CARISOPRODOL	TABLET	350MG
30 CEFDINIR	CAPSULE	300MG
30 CEFDINIR	SOLUTION	125MG/5ML

30	CEFDINIR	SOLUTION	250MG/5ML
31	CEFPROZIL	TABLET	250MG
31	CEFPROZIL	TABLET	500MG
32	CEFUROXIME AXETIL	TABLET	250MG
32	CEFUROXIME AXETIL	TABLET	500MG
33	CELECOXIB	CAPSULE	100MG
33	CELECOXIB	CAPSULE	200MG
33	CELECOXIB	CAPSULE	400MG
33	CELECOXIB	CAPSULE	50MG
34	CEPHALEXIN (CEFALEXIN)	SOLUTION	125MG/5ML
34	CEPHALEXIN (CEFALEXIN)	SOLUTION	250MG/5ML
35	CHLORPROMAZINE HCL	TABLET	100MG
35	CHLORPROMAZINE HCL	TABLET	10MG
35	CHLORPROMAZINE HCL	TABLET	200MG
35	CHLORPROMAZINE HCL	TABLET	25MG
35	CHLORPROMAZINE HCL	TABLET	50MG
36	CHOLESTYRAMINE	PACKET/ORAL SOLID	4G
36	CHOLESTYRAMINE	POWDER	4G
37	CICLOPIROX	CREAM	0.77%
37	CICLOPIROX	SHAMPOO	1%
37	CICLOPIROX	SOLUTION	8%
38	CIMETIDINE	TABLET	200MG
38	CIMETIDINE	TABLET	300MG
38	CIMETIDINE	TABLET	400MG
38	CIMETIDINE	TABLET	800MG
39	CLARITHROMYCIN ER	TABLET	500MG
40	CLINDAMYCIN PHOSPHATE	GEL	1%
40	CLINDAMYCIN PHOSPHATE	LOTION	1%
40	CLINDAMYCIN PHOSPHATE	SOLUTION	1%
40	CLINDAMYCIN PHOSPHATE	VAGINAL CREAM	2%
41	CLOBETASOL	CREAM	0.05%
41	CLOBETASOL	E CREAM	0.05%
41	CLOBETASOL	GEL	0.05%
41	CLOBETASOL	OINTMENT	0.05%
41	CLOBETASOL	SOLUTION	0.05%
42	CLOMIPRAMINE	CAPSULE	25MG
42	CLOMIPRAMINE	CAPSULE	50MG
42	CLOMIPRAMINE	CAPSULE	75MG
43	CLONIDINE ER	PATCH	0.1MG/24HR
43	CLONIDINE ER	PATCH	0.2MG/24HR
43	CLONIDINE ER	PATCH	0.3MG/24HR
44	CLOTRIMAZOLE	SOLUTION	1%
45	DESMOPRESSIN ACETATE	TABLET	0.1MG
45	DESMOPRESSIN ACETATE	TABLET	0.2MG
46	DESONIDE	CREAM	0.05%
46	DESONIDE	LOTION	0.05%
46	DESONIDE	OINTMENT	0.05%
47	DESOXIMETASONE	OINTMENT	0.25%
48	DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	15MG
48	DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	20MG
48	DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	40MG
48	DEXMETHYLPHENIDATE HCL ER (DEXMETH ER) (FOCALIN)	CAPSULE	5MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	10MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	15MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	2.5MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	20MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	30MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	5MG
49	DEXTROAMPHETAMINE SULFATE (DEX SULFATE)	TABLET	7.5MG
49	DEXTROAMPHETAMINE SULFATE ER (DEX SULFATE ER)	CAPSULE	10MG
49	DEXTROAMPHETAMINE SULFATE ER (DEX SULFATE ER)	CAPSULE	15MG
49	DEXTROAMPHETAMINE SULFATE ER (DEX SULFATE ER)	CAPSULE	5MG
50	DICLOFENAC POTASSIUM	TABLET	50MG
51	DIGOXIN	TABLET	0.125MG
51	DIGOXIN	TABLET	0.25MG
52	DILTIAZEM HCL	TABLET	120MG
52	DILTIAZEM HCL	TABLET	30MG
52	DILTIAZEM HCL	TABLET	60MG
52	DILTIAZEM HCL	TABLET	90MG
53	DIPHENOXYLATE/ATROPINE	TABLET	2.5MG;0.025MG
54	DIVALPROEX ER	TABLET	250MG
54	DIVALPROEX ER	TABLET	500MG
55	DOXAZOSIN MESYLATE	TABLET	1MG
55	DOXAZOSIN MESYLATE	TABLET	2MG
55	DOXAZOSIN MESYLATE	TABLET	4MG
55	DOXAZOSIN MESYLATE	TABLET	8MG
56	DOXYCYCLINE HYCLATE	CAPSULE	100MG
56	DOXYCYCLINE HYCLATE	CAPSULE	50MG
56	DOXYCYCLINE HYCLATE	TABLET	100MG
56	DOXYCYCLINE HYCLATE DR	TABLET	100MG
56	DOXYCYCLINE HYCLATE DR	TABLET	150MG
56	DOXYCYCLINE HYCLATE DR	TABLET	75MG
56	DOXYCYCLINE MONOHYDRATE	TABLET	100MG
56	DOXYCYCLINE MONOHYDRATE	TABLET	150MG
56	DOXYCYCLINE MONOHYDRATE	TABLET	50MG
56	DOXYCYCLINE MONOHYDRATE	TABLET	75MG
57	DROSPIRENONE/ETHINYL ESTRADIOL (OCELLA)	TABLET	3MG-0.02MG
57	DROSPIRENONE/ETHINYL ESTRADIOL (OCELLA)	TABLET	3MG-0.03MG
58	ECONAZOLE	CREAM	1%
59	ENALAPRIL MALEATE	TABLET	10MG
59	ENALAPRIL MALEATE	TABLET	2.5MG
59	ENALAPRIL MALEATE	TABLET	20MG
59	ENALAPRIL MALEATE	TABLET	5MG

60 ENTECAVIR	TABLET	0.5MG
60 ENTECAVIR	TABLET	1MG
61 ESTRADIOL	TABLET	0.5MG
61 ESTRADIOL	TABLET	1MG
61 ESTRADIOL	TABLET	2MG
62 ESTRADIOL/NORETHINDRONE ACETATE (MIMVEY)	TABLET	1MG-0.5MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-0.1MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.03MG-.15MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.03MG-.15MG-.01MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-0.1MG-.01MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-.15MG;.025MG-.15MG;.03MG-.15MG;.01MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.03MG-.05MG;.04MG-.075MG;.03MG-.125MG
63 ETHINYL ESTRADIOL/LEVONORGESTREL (PORTIA,JOLESSA)	TABLET	.02MG-.09MG
64 ETODOLAC	CAPSULE	200MG
64 ETODOLAC	CAPSULE	300MG
64 ETODOLAC	TABLET	400MG
64 ETODOLAC	TABLET	500MG
64 ETODOLAC ER	TABLET	400MG
64 ETODOLAC ER	TABLET	500MG
64 ETODOLAC ER	TABLET	600MG
65 EXEMESTANE	TABLET	25MG
66 FENOFIBRATE	TABLET	145MG
66 FENOFIBRATE	TABLET	48MG
67 FLUCONAZOLE	TABLET	100MG
67 FLUCONAZOLE	TABLET	150MG
67 FLUCONAZOLE	TABLET	200MG
67 FLUCONAZOLE	TABLET	50MG
68 FLUOCINOLONE ACETONIDE	CREAM	0.01%
68 FLUOCINOLONE ACETONIDE	CREAM	0.025%
68 FLUOCINOLONE ACETONIDE	OINTMENT	0.025%
68 FLUOCINOLONE ACETONIDE	SOLUTION	0.01%
69 FLUOCINONIDE	CREAM	0.05%
69 FLUOCINONIDE	CREAM	0.1%
69 FLUOCINONIDE	E CREAM	0.05%
69 FLUOCINONIDE	GEL	0.05%
69 FLUOCINONIDE	OINTMENT	0.05%
69 FLUOCINONIDE	SOLUTION	0.05%
70 FLUOXETINE HCL	TABLET	10MG
70 FLUOXETINE HCL	TABLET	15MG
70 FLUOXETINE HCL	TABLET	20MG
70 FLUOXETINE HCL	TABLET	60MG
71 FLUTICASONE PROPIONATE	SPRAY	50MCG
72 FOSINOPRIL HCTZ	TABLET	10MG;12.5MG
72 FOSINOPRIL HCTZ	TABLET	20MG;12.5MG
73 GABAPENTIN	TABLET	600MG
73 GABAPENTIN	TABLET	800MG
74 GLIMEPIRIDE	TABLET	1MG
74 GLIMEPIRIDE	TABLET	2MG
74 GLIMEPIRIDE	TABLET	4MG
75 GLIPIZIDE/METFORMIN	TABLET	2.5MG;250MG
75 GLIPIZIDE/METFORMIN	TABLET	2.5MG;500MG
75 GLIPIZIDE/METFORMIN	TABLET	5MG;500MG
76 GLYBURIDE	TABLET	1.25MG
76 GLYBURIDE	TABLET	2.5MG
76 GLYBURIDE	TABLET	5MG
77 GLYBURIDE/METFORMIN	TABLET	1.25MG;250MG
77 GLYBURIDE/METFORMIN	TABLET	2.5MG;500MG
77 GLYBURIDE/METFORMIN	TABLET	5MG;500MG
78 GRISEOFULVIN	SUSPENSION (MICROSIZE)	125MG/5ML
79 HALOBETASOL PROPIONATE	CREAM	0.05%
79 HALOBETASOL PROPIONATE	OINTMENT	0.05%
80 HALOPERIDOL	TABLET	0.5MG
80 HALOPERIDOL	TABLET	10MG
80 HALOPERIDOL	TABLET	1MG
80 HALOPERIDOL	TABLET	20MG
80 HALOPERIDOL	TABLET	2MG
80 HALOPERIDOL	TABLET	5MG
81 HYDROCODONE/ACETAMINOPHEN	TABLET	325MG;10MG
81 HYDROCODONE/ACETAMINOPHEN	TABLET	325MG;5MG
82 HYDROCORTISONE VALERATE	CREAM	0.2%
83 IRBESARTAN	TABLET	150MG
83 IRBESARTAN	TABLET	300MG
83 IRBESARTAN	TABLET	75MG
84 ISOSORBIDE DINITRATE	TABLET	10MG
84 ISOSORBIDE DINITRATE	TABLET	20MG
84 ISOSORBIDE DINITRATE	TABLET	30MG
84 ISOSORBIDE DINITRATE	TABLET	5MG
85 KETOCONAZOLE	CREAM	2%
85 KETOCONAZOLE	TABLET	200MG
86 KETOPROFEN	CAPSULE	50MG
86 KETOPROFEN	CAPSULE	75MG
87 KETOROLAC TROMETHAMINE	TABLET	10MG
88 LABETALOL HCL	TABLET	100MG
88 LABETALOL HCL	TABLET	200MG
88 LABETALOL HCL	TABLET	300MG
89 LAMIVUDINE/ZIDOVUDINE (COMBIVIR)	TABLET	150MG;300MG
89 LAMIVUDINE/ZIDOVUDINE (COMBIVIR)	TABLET	300MG;150MG
90 LATANOPROST	SOLUTION	0.005%
91 LEFLUNOMIDE	TABLET	10MG
91 LEFLUNOMIDE	TABLET	20MG
92 LEVOTHYROXINE	TABLET	0.025MG
92 LEVOTHYROXINE	TABLET	0.05MG



92	LEVOTHYROXINE	TABLET	0.075MG
92	LEVOTHYROXINE	TABLET	0.088MG
92	LEVOTHYROXINE	TABLET	0.112MG
92	LEVOTHYROXINE	TABLET	0.125MG
92	LEVOTHYROXINE	TABLET	0.137MG
92	LEVOTHYROXINE	TABLET	0.15MG
92	LEVOTHYROXINE	TABLET	0.175MG
92	LEVOTHYROXINE	TABLET	0.1MG
92	LEVOTHYROXINE	TABLET	0.2MG
92	LEVOTHYROXINE	TABLET	0.3MG
93	LIDOCAINE HCL	OINTMENT	5%
94	LIDOCAINE/PRILOCAINE	CREAM	2.5%;2.5%
95	LOPERAMIDE HCL	CAPSULE	2MG
96	MEPROBAMATE	TABLET	200MG
96	MEPROBAMATE	TABLET	400MG
97	METFORMIN (F) ER	TABLET	1000MG
97	METFORMIN (F) ER	TABLET	500MG
98	METHADONE HCL	TABLET	10MG
98	METHADONE HCL	TABLET	5MG
99	METHAZOLAMIDE	TABLET	25MG
99	METHAZOLAMIDE	TABLET	50MG
100	METHOTREXATE	TABLET	2.5MG
101	METHYLPHENIDATE	TABLET	10MG
101	METHYLPHENIDATE	TABLET	20MG
101	METHYLPHENIDATE	TABLET	5MG
101	METHYLPHENIDATE ER	TABLET	20MG
102	METHYLPREDNISOLONE	TABLET	4MG
103	METRONIDAZOLE	CREAM	0.75%
103	METRONIDAZOLE	GEL	0.75%
103	METRONIDAZOLE	GEL	1%
103	METRONIDAZOLE	GEL VAGINAL	0.75%
103	METRONIDAZOLE	LOTION	0.75%
104	MOEXIPRIL HCL	TABLET	15MG
104	MOEXIPRIL HCL	TABLET	7.5MG
105	MOEXIPRIL HCL/HCTZ	TABLET	15MG;12.5MG
105	MOEXIPRIL HCL/HCTZ	TABLET	15MG;25MG
105	MOEXIPRIL HCL/HCTZ	TABLET	7.5MG;12.5MG
106	NADOLOL	TABLET	20MG
106	NADOLOL	TABLET	40MG
106	NADOLOL	TABLET	80MG
107	NAPROXEN SODIUM	TABLET	275MG
107	NAPROXEN SODIUM	TABLET	550MG
108	NEOMYCIN/POLYMYXIN/HYDROCORTISONE	SOLUTION	3.5MG;10MU;1%
109	NIACIN ER	TABLET	1000MG
109	NIACIN ER	TABLET	500MG
109	NIACIN ER	TABLET	750MG
110	NIMODIPINE	CAPSULE	30MG
111	NITROFURANTOIN/MACROCRYSTALLINE	CAPSULE	100MG
111	NITROFURANTOIN/MACROCRYSTALLINE	CAPSULE	25MG
111	NITROFURANTOIN/MACROCRYSTALLINE	CAPSULE	50MG
112	NORETHINDRONE/ETHINYL ESTRADIOL (BALZIVA)	TABLET	0.4MG-0.035MG
113	NORTRIPTYLINE HCL	CAPSULE	10MG
113	NORTRIPTYLINE HCL	CAPSULE	25MG
113	NORTRIPTYLINE HCL	CAPSULE	50MG
113	NORTRIPTYLINE HCL	CAPSULE	75MG
114	NYSTATIN	CREAM	100MU
114	NYSTATIN	OINTMENT	100MU
114	NYSTATIN	TABLET	500MU
115	NYSTATIN/TRIAMCINOLONE	CREAM	0.1%
115	NYSTATIN/TRIAMCINOLONE	OINTMENT	0.1%
116	OMEGA 3 ACID ETHYL ESTERS	CAPSULE	1G
117	OXAPROZIN	TABLET	600MG
118	OXYBUTYNIN CHLORIDE	TABLET	5MG
119	OXYCODONE/ACETAMINOPHEN	TABLET	10MG;325MG
119	OXYCODONE/ACETAMINOPHEN	TABLET	5MG;325MG
119	OXYCODONE/ACETAMINOPHEN	TABLET	7.5MG;325MG
120	OXYCODONE HCL	SOLUTION	20MG/ML
120	OXYCODONE HCL	TABLET	15MG
120	OXYCODONE HCL	TABLET	30MG
121	PARICALCITOL	CAPSULE	1MCG
121	PARICALCITOL	CAPSULE	2MCG
121	PARICALCITOL	CAPSULE	4MCG
122	PAROMOMYCIN	CAPSULE	250MG
123	PERMETHRIN	CREAM	5%
124	PERPHENAZINE	TABLET	16MG
124	PERPHENAZINE	TABLET	2MG
124	PERPHENAZINE	TABLET	4MG
124	PERPHENAZINE	TABLET	8MG
125	PHENYTOIN SODIUM ER	CAPSULE	100MG
126	PILOCARPINE HCL	TABLET	5MG
127	PIROXICAM	CAPSULE	10MG
127	PIROXICAM	CAPSULE	20MG
128	POTASSIUM CHLORIDE ER	TABLET	10MEQ
128	POTASSIUM CHLORIDE ER	TABLET	20MEQ
128	POTASSIUM CHLORIDE ER	TABLET	8MEQ
129	PRAVASTATIN	TABLET	10MG
129	PRAVASTATIN	TABLET	20MG
129	PRAVASTATIN	TABLET	40MG
129	PRAVASTATIN	TABLET	80MG
130	PRAZOSIN HCL	CAPSULE	1MG
130	PRAZOSIN HCL	CAPSULE	2MG
130	PRAZOSIN HCL	CAPSULE	5MG

131 PREDNISOLONE ACETATE	SOLUTION/LIQUID EYE	1%
132 PREDNISONE	TABLET	10MG
132 PREDNISONE	TABLET	1MG
132 PREDNISONE	TABLET	2.5MG
132 PREDNISONE	TABLET	20MG
132 PREDNISONE	TABLET	5MG
133 PROCHLORPERAZINE	SUPPOSITORY	25MG
134 PROMETHAZINE	SUPPOSITORY	12.5MG
134 PROMETHAZINE	SUPPOSITORY	25MG
135 PROPRANOLOL	TABLET	10MG
135 PROPRANOLOL	TABLET	20MG
135 PROPRANOLOL	TABLET	40MG
135 PROPRANOLOL	TABLET	60MG
135 PROPRANOLOL	TABLET	80MG
135 PROPRANOLOL ER	CAPSULE	120MG
135 PROPRANOLOL ER	CAPSULE	160MG
135 PROPRANOLOL ER	CAPSULE	60MG
135 PROPRANOLOL ER	CAPSULE	80MG
136 RALOXIFENE HCL	TABLET	60MG
137 RANITIDINE HCL	CAPSULE	150MG
137 RANITIDINE HCL	CAPSULE	300MG
137 RANITIDINE HCL	TABLET	150MG
138 SILVER SULFADIAZINE	CREAM	1%
139 SPIRONOLACTONE/HCTZ	TABLET	25MG;25MG
140 TACROLIMUS	OINTMENT	0.03%
140 TACROLIMUS	OINTMENT	0.1%
141 TAMOXIFEN CITRATE	TABLET	10MG
141 TAMOXIFEN CITRATE	TABLET	20MG
142 TEMOZOLOMIDE	CAPSULE	100MG
142 TEMOZOLOMIDE	CAPSULE	140MG
142 TEMOZOLOMIDE	CAPSULE	180MG
142 TEMOZOLOMIDE	CAPSULE	20MG
142 TEMOZOLOMIDE	CAPSULE	250MG
142 TEMOZOLOMIDE	CAPSULE	5MG
143 TERCONAZOLE	VAGINAL CREAM	0.4%
143 TERCONAZOLE	VAGINAL CREAM	0.8%
144 THEOPHYLLINE ER	TABLET	100MG
144 THEOPHYLLINE ER	TABLET	200MG
144 THEOPHYLLINE ER	TABLET	300MG
144 THEOPHYLLINE ER	TABLET	400MG
144 THEOPHYLLINE ER	TABLET	450MG
144 THEOPHYLLINE ER	TABLET	600MG
145 TIMOLOL MALEATE	GEL	0.25%
145 TIMOLOL MALEATE	GEL	0.5%
146 TIZANIDINE HCL	TABLET	2MG
146 TIZANIDINE HCL	TABLET	4MG
147 TOBRAMYCIN	SOLUTION	300MG/5ML
148 TOBRAMYCIN/DEXAMETHASONE	SOLUTION	0.3;0.1%
149 TOLMETIN SODIUM	CAPSULE	400MG
150 TOLTERODINE TARTRATE	TABLET	1MG
150 TOLTERODINE TARTRATE	TABLET	2MG
150 TOLTERODINE TARTRATE ER	CAPSULE	2MG
150 TOLTERODINE TARTRATE ER	CAPSULE	4MG
151 TRAZODONE HCL	TABLET	100MG
152 TRIAMCINOLONE ACETONIDE	CREAM	0.025%
152 TRIAMCINOLONE ACETONIDE	CREAM	0.1%
152 TRIAMCINOLONE ACETONIDE	CREAM	0.5%
152 TRIAMCINOLONE ACETONIDE	OINTMENT	0.025%
152 TRIAMCINOLONE ACETONIDE	OINTMENT	0.1%
152 TRIAMCINOLONE ACETONIDE	OINTMENT	0.5%
153 TRIAMTERENE/HCTZ	CAPSULE	37.5MG;25MG
153 TRIAMTERENE/HCTZ	TABLET	37.5MG;25MG
153 TRIAMTERENE/HCTZ	TABLET	75MG;50MG
154 TRIFLUOPERAZINE HCL	TABLET	10MG
154 TRIFLUOPERAZINE HCL	TABLET	1MG
154 TRIFLUOPERAZINE HCL	TABLET	2MG
154 TRIFLUOPERAZINE HCL	TABLET	5MG
155 URSODIOL	CAPSULE	300MG
156 VALSARTAN HCTZ	TABLET	160MG;12.5MG
156 VALSARTAN HCTZ	TABLET	160MG;25MG
156 VALSARTAN HCTZ	TABLET	320MG;12.5MG
156 VALSARTAN HCTZ	TABLET	320MG;25MG
156 VALSARTAN HCTZ	TABLET	80MG;12.5MG
157 VERAPAMIL	TABLET	120MG
157 VERAPAMIL	TABLET	80MG
157 VERAPAMIL SR	CAPSULE	120MG
157 VERAPAMIL SR	CAPSULE	180MG
157 VERAPAMIL SR	CAPSULE	240MG
158 WARFARIN SODIUM	TABLET	10MG
158 WARFARIN SODIUM	TABLET	1MG
158 WARFARIN SODIUM	TABLET	2.5MG
158 WARFARIN SODIUM	TABLET	2MG
158 WARFARIN SODIUM	TABLET	3MG
158 WARFARIN SODIUM	TABLET	4MG
158 WARFARIN SODIUM	TABLET	5MG
158 WARFARIN SODIUM	TABLET	6MG
158 WARFARIN SODIUM	TABLET	7.5MG
159 ZOLEDRONIC ACID	IV CONCENTRATE	4MG/5ML
159 ZOLEDRONIC ACID	IV SOLUTION	5MG/100ML

**APPENDIX B: NAMED DEFENDANTS**

1. Actavis Holdco U.S., Inc.
2. Actavis Pharma, Inc.
3. Actavis Elizabeth, LLC
4. Akorn Inc.
5. Alvogen Inc.
6. Amneal Pharmaceuticals, Inc.
7. Amneal Pharmaceuticals, LLC
8. Apotex Corp.
9. Ascend Laboratories, LLC
10. Aurobindo Pharma USA, Inc.
11. Bausch Health Americas, Inc.
12. Bausch Health US, LLC
13. Breckenridge Pharmaceutical, Inc.
14. Camber Pharmaceuticals Inc.
15. Citron Pharma LLC
16. Dava Pharmaceuticals, LLC
17. Dr. Reddy's Laboratories, Inc.
18. Epic Pharma, LLC
19. Fougera Pharmaceuticals Inc.
20. Generics Bidco I LLC
21. Glenmark Pharmaceuticals Inc., USA
22. Greenstone LLC
23. G&W Laboratories, Inc.
24. Heritage Pharmaceuticals, Inc.
25. Hikma Labs, Inc.
26. Hikma Pharmaceuticals USA, Inc.
27. Hi-Tech Pharmacal Co., Inc.
28. Impax Laboratories, Inc.
29. Impax Laboratories, LLC
30. Jubilant Cadista Pharmaceuticals Inc.
31. Lannett Company, Inc.
32. Lupin Pharmaceuticals, Inc.
33. Mallinckrodt Inc.
34. Mayne Pharma Inc.
35. Morton Grove Pharmaceuticals, Inc.
36. Mylan Inc.
37. Mylan Pharmaceuticals Inc.
38. Oceanside Pharmaceuticals, Inc.
39. Par Pharmaceutical Companies, Inc.
40. Par Pharmaceutical, Inc.
41. Perrigo New York, Inc.
42. Pfizer, Inc.
43. Pliva, Inc.
44. Sandoz, Inc.
45. Sun Pharmaceutical Industries, Inc.
46. Taro Pharmaceuticals U.S.A., Inc.
47. Teligent Inc.
48. Teva Pharmaceuticals USA, Inc.
49. Torrent Pharma Inc.
50. UDL Laboratories, Inc.
51. Upsher-Smith Laboratories, Inc.
52. Valeant Pharmaceuticals International
53. Valeant Pharmaceuticals North America LLC
54. Versapharm, Inc.
55. West-Ward Columbus, Inc.
56. West-Ward Pharmaceuticals Corp.
57. Wockhardt USA LLC
58. Zydus Pharmaceuticals (USA), Inc.

Generic Pharmaceuticals Pricing Antitrust Litigation  
c/o A.B. Data, Ltd.  
P.O. Box 173095  
Milwaukee, WI 53217

PRESORT  
FIRST CLASS MAIL  
US POSTAGE  
PAID  
MILWAUKEE, WI  
PERMIT 3780

CHANGE SERVICE REQUESTED

**COURT APPROVED NOTICE REGARDING**  
*Generic Pharmaceuticals Pricing Antitrust Litigation*



1\* 1 \*\*\*\*\* ALL FOR AADC 535



NOTICE ID: [REDACTED]

[REDACTED]  
[REDACTED]  
[REDACTED]

# EXHIBIT B

**Did You Purchase Certain Named GENERIC PHARMACEUTICAL DRUGS DIRECTLY from Certain Pharmaceutical Manufacturers?**  
 YOUR RIGHTS MAY BE AFFECTED BY A PROPOSED CLASS ACTION SETTLEMENT  
 LEARN MORE →  
 GenericDrugsDirectPurchaserSettlement.com

### Featured Stories



10 Jul 2024 | NEWS

#### Congress Pushes US FDA On Trial Diversity, Accelerated Approval In Approps Report

By Sarah Karlin-Smith

The House Appropriations Committee indicates in fiscal year 2025 appropriations report language that lawmakers will closely monitor the FDA's implementation of clinical trial

Legislation | Rare Diseases | Regulation



10 Jul 2024 | ANALYSIS

#### FTC's PBM Investigation Could Yield Litigation Over Insulin

#### Latest News

FTC's PBM Investigation Could Yield Litigation Over Insulin Contracting  
13 hours ago

Congress Pushes US FDA On Trial Diversity, Accelerated Approval In Approps Report  
13 hours ago

Approval Geography: Novel Agent Landscape Across US And EU  
13 hours ago

Novo Nordisk UK In Trouble Again, This Time For Failing To Disclose Payments  
13 hours ago

Hong Kong Enhances Expedited Drug Licensing Process; Adopts Refuse-To-File Tool  
21 hours ago

By Cathy Kelly

The US Federal Trade Commission's focus on potential anti-competitive behavior by pharmacy benefit managers picks up steam as Chair Lina Khan approaches the end of her

Reimbursement | Pricing Debate | Policy

Next R&D Funding Framework  
21 hours ago

SEE ALL



10 Jul 2024 | DATA

#### Approval Geography: Novel Agent Landscape Across US And EU

By Bridget Silverman and Nancy Pham

Pink Sheet infographic shows how a large majority of novel drugs make it past the US FDA before receiving approval in the European Union. Lag times ranged from almost five years to

Regional Comparisons | Approvals | Regulation

ADVERTISEMENT



Did You Purchase Certain Named **GENERIC PHARMACEUTICAL DRUGS** DIRECTLY from Certain Pharmaceutical Manufacturers?

YOUR RIGHTS MAY BE AFFECTED BY A PROPOSED CLASS ACTION SETTLEMENT

LEARN MORE →

GenericDrugsDirectPurchaserSettlement.com

### Diversity Action Plans



# EXHIBIT C

BIGGEST 1,000 STOCKS

Continued From Page B7. Table with 14 columns: Stock, Sym, Close, Net Chg, Stock, Sym, Close, Net Chg, Stock, Sym, Close, Net Chg, Stock, Sym, Close, Net Chg, Stock, Sym, Close, Net Chg, Stock, Sym, Close, Net Chg. Includes sub-sections O P Q, R S, and T U V.

ADVERTISEMENT

The Marketplace
To advertise: 800-366-3975 or WSJ.com/classifieds

CLASS ACTION

If You Purchased Certain Named Generic Pharmaceutical Drugs
Directly from Certain Pharmaceutical Manufacturers
from May 1, 2009 through December 31, 2019,
Your Rights May Be Affected by a Proposed Class Action Settlement.

What is the lawsuit about? A proposed Settlement has been reached in a class action lawsuit ("the Lawsuit"), which alleges that Sandoz Inc. and Fougera Pharmaceuticals Inc. (collectively "Settling Defendants") and other generic drug manufacturers violated the federal antitrust laws by conspiring to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs (the "Named Generic Drugs")...

Who is included? The Court has certified a Settlement Class that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Current or Former Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 through December 31, 2019. Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities. The Settlement Agreement listing the Named Generic Drugs and Current and Former Defendants is available on the Settlement website: GenericDrugsDirectPurchaserSettlement.com...

What does the Settlement provide? The proposed Settlement provides for a \$265,000,000.00 payment by Settling Defendants ("Settlement Fund"). The Settlement Fund may be reduced to \$233,200,000.00 or increased to a maximum of \$327,351,850.00 under certain circumstances as explained in the Settlement Agreement. In addition, the Direct Purchaser Plaintiff ("DPP") attorneys who have worked on the Lawsuit for the Settlement Classes will seek Court approval to pay expenses, and service awards for the class representatives (or named plaintiffs) out of the Settlement Fund. DPP attorneys will also request attorneys' fees up to one-third of the net Settlement Fund, including interest, after expenses (and service awards) are deducted, and any portions of the Settlement Funds created from DPPs' prior Settlements that have been set aside pursuant to Court Order. Any motion for fees, expenses and service awards will be posted on the Settlement website GenericDrugsDirectPurchaserSettlement.com no later than November 22, 2024. The calculations of the dollar amount that each Settlement Class Member will be paid from the Settlement Fund are set forth in the Plan of Allocation, which also is available on GenericDrugsDirectPurchaserSettlement.com.

What are your options? If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and are eligible to participate in the Settlement as described in this notice, if the Settlement is approved. However, you will need to complete, sign, and return the claim form (once it is sent to you) in order to obtain a payment. We do not know when the claim forms will be mailed. You should check GenericDrugsDirectPurchaserSettlement.com for information regarding timing. If you did not receive a Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter to the following address: In re: Generic Pharmaceuticals Pricing Antitrust Litigation - Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 1730955, Milwaukee, WI 53217. Or send an email to info@GenericDrugsDirectPurchaserSettlement.com, or call 877-315-0583. You may be required to submit proof of a qualifying direct purchase to establish that you are a Settlement Class Member. Such claimants may also be required to submit purchase data as part of the claims process. As a Settlement Class Member, unless you opt out of the Settlement, you will be bound by all orders and judgments of the Court.

In addition, if you are a Settlement Class Member, you may request exclusion from (or opt out of) the Settlement, and if you do not opt out, you may also object to the Settlement. Instructions for opting-out or objecting can be found in the publicly available case file and website, as described above. You must mail your request to opt out or your objection by October 8, 2024. The Court will hold a Fairness Hearing on March 17, 2025, to decide whether to approve the Settlement and by October 8, 2024. The Court will also consider a Plan of Allocation for distributing the Settlement Fund to Settlement Class Members. If there are objections, the Court will consider them at the hearing. You do not need to attend the hearing. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court and you may hire your own attorney to appear in Court for you at your own expense.

For more information: Go to the website: GenericDrugsDirectPurchaserSettlement.com or call 877-315-0583 for more information on the Settlement, the lawsuit, and your potential rights and options related to the Settlement, and the Plan of Allocation. The website includes, for example, a list of the generic drugs that you would have had to purchase and a list of the generic manufacturers that you would have had to purchase directly from in order to be eligible for a payment.

ANNOUNCEMENTS
We Write Your Book
Life Story or the Story of Your Success in Business + Lessons Learned + Advice for Others. LegaciesandMemories.com BizSuccessBooks.com (904) 293-9893 Since 1999

BUSINESS OPPORTUNITIES
2ND TRUST DEED
12% RETURN
42% L.T.V. • 2 YEARS
IRVINE, CA
CUSTOM HOME
866-700-0600
Alliance Portfolio
120 Veritas Dr., Ste. 515 • Alliso Viejo, CA 92656 www.AlliancePortfolio.com RE Broker • CA DRE • 02066955 Broker License ID

DEA
LEGAL NOTICE
DEA NOTICE OF FORFEITURE
SOUTHERN DISTRICT OF TEXAS
2016 Cadillac XTS Sedan
VIN 2G61N5S3XG9103634
Seized from Leandro Antonio Taboramendez on 03/24/2021 at 7218 Foxcrest Lane, Humble, TX. Any person asserting an ownership or possessory interest and desiring to claim the above vehicle has 30 days from the date of the first publication to file a claim with DEA at 1433 West Loop South, Suite 600, Houston, TX 77027. Attn: DEA/ARG.

NOTICE OF SALE

NOTICE OF PUBLIC SALE OF COLLATERAL
NOTICE IS HEREBY GIVEN that, pursuant to: (a) Section 9-610 of the Uniform Commercial Code ("UCC") as in effect in the State of New York and (b) the Security Agreement dated as of June 2, 2022 (as amended, supplemented or otherwise modified, the "Security Agreement"), by and among, Moshe Silber, an individual (the "Borrower"), Westwood Jackson Apts MM LLC, a Delaware limited liability company ("Westwood MM"), and CBRM Realty Inc., a New York corporation ("CBRM"), and together with the Borrower and Westwood MM, the "Debtors", the other debtors party thereto, and Acquium Agency Services LLC, as secured party (the "Secured Party"), the Secured Party will offer for sale at public sales (such sales, collectively, the "Auction") all right, title and interest of the Debtors in and to the following collateral (the "Subject Collateral"): (i) Lot 1 consisting of 100% of the limited liability company membership interests in RH Dearborn Redevelopment JV LLC, a Delaware limited liability company, and all proceeds (as defined in the UCC) thereof; (ii) Lot 2 consisting of 100% of the limited liability company membership interests in Fox Capital LLC, a New York limited liability company, and all proceeds thereof; (iii) Lot 3 consisting of (x) 100% of the limited liability company membership interests in Westwood Jackson Apts MM LLC, a Delaware limited liability company, and all proceeds thereof, and (y) 100% of the limited liability company membership interests in Westwood Jackson Apts LLC, a Delaware limited liability company, and all proceeds of the foregoing. The Sales will be held at 10:00 A.M. Eastern Standard Time on the date and at the location set forth below. The Secured Party reserves the right to amend, supplement or otherwise modify, the "Credit Agreement", among the Borrower, the lenders party thereto, and Acquium Agency Services LLC, as administrative agent, the "Credit Agreement".

TERMS AND CONDITIONS OF THE AUCTION
The Subject Collateral is being sold in four separate lots as described above on an "AS IS, WHERE IS, WITH ALL FAULTS" basis pursuant to the following terms and conditions.
1. Parties interested in bidding at the Auction may subject to executing confidentiality agreements and meeting the bidder qualifications set forth in the bidding procedures (the "Bidding Procedures"), which can be obtained by contacting CDR Capital Markets, Inc. ("CDR") as provided below, obtain additional information concerning the Subject Collateral by contacting CBRM. The Bidding Procedures provide additional information about the bidding process, including bidder qualifications, Auction participation and determination of the winning bid.
2. The Auction will be held on July 25, 2024 at 10:00 A.M. (New York City time) via a web-based video conferencing and/or telephonic conferencing program selected by the Secured Party access to which will be made available to qualified bidders.
3. The Subject Collateral will be sold on an "AS-IS, WHERE-IS, WITH ALL FAULTS" basis, without recourse, and without any express or implied representations or warranties whatsoever, including, without limitation, as to the condition of title, value, or quality of the Subject Collateral, or without regard to assets, liabilities, financial condition, or earnings of any Debtor or any of their affiliates. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, ALL WARRANTIES, WHETHER OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR OTHERWISE, ARE EXPRESSLY DISCLAIMED. The Sale of the Subject Collateral is specifically subject to all taxes, liens (other than those of the Secured Party), claims, assessments, liabilities and encumbrances, if any, that may exist against the Subject Collateral under the UCC or other applicable law. The Secured Party makes no representations or warranties and provides no assurances as to any Subject Collateral. Prospective bidders should perform their own diligence as to the Subject Collateral.
4. The Secured Party reserves the right to determine which bidders qualify for participation in the Auction, reject any bid or all bids at the Auction, to announce such other terms at the Auction as may be commercially reasonable in the Secured Party's discretion or to accept non-conforming bids. Further, the Secured Party reserves the right to cancel, postpone or adjourn the Auction by announcement made at the Auction, either before or after the commencement of bidding, without written notice or further publication. The Secured Party reserves the right to credit bid any portion of its secured indebtedness then outstanding under the Credit Agreements at the Auction. The Secured Party reserves the right to implement such other terms or conditions at the Auction or regarding the Auction procedures as the Secured Party, in its sole discretion, determine to be commercially reasonable under the circumstances.
All inquiries concerning this Notice of Public Sale and the terms and conditions of the sale (including requests to be a "qualified bidder") should be made to: CDR Capital Markets at CDR@ccsales.com. Any person making any inquiry or request must: (i) disclose the person or entity on whose behalf such information is being sought; (ii) execute the confidentiality agreement, which can be reviewed at the website https://forms.silverthru.com/Silverthru (case sensitive); and (iii) maintain the confidentiality of the information provided in accordance with the confidentiality agreement.

Dividend Changes

Table with 5 columns: Company, Symbol, Yld %, Amount New/Old, Payable/Record. Includes rows for MV Oil Trust, HOOKIPA Pharma, Banco BBVA Argentina ADR, etc.

BANKRATE.COM MMA, Savings and CDs

Table with 10 columns: Type, MMA, 1-MO, 2-MO, 3-MO, 6-MO, 1-YR, 2-YR, 25YR, 5YR. Includes rows for National average, Weekly change, Savings, Jumbos.

Consumer Savings Rates

Below are the top federally insured offers available nationwide according to Bankrate.com's weekly survey of highest yields. For latest offers and reviews of these financial institutions, please visit bankrate.com/banking/reviews. Information is believed to be reliable, but not guaranteed.

High yield savings

Table with 10 columns: Bank, Phone number, Minimum, Yield (%), Bank, Phone number, Minimum, Yield (%). Includes rows for MyBankingDirect, Forbriht Bank, One-month CD, Two-month CD, Three-month CD.

High yield jumbos - Minimum is \$100,000

Table with 10 columns: Bank, Phone number, Minimum, Yield (%), Bank, Phone number, Minimum, Yield (%). Includes rows for Money market account, Six-month CD, Two-year CD, Five-year CD.

THE WALL STREET JOURNAL. THE MARKETPLACE ADVERTISE TODAY (800) 366-3975 For more information visit: wsj.com/classifieds



# EXHIBIT D

# Direct Purchaser Plaintiffs Announce an Additional Settlement in In Re Generic Pharmaceutical Pricing Antitrust Litigation

---

NEWS PROVIDED BY

**Nast Law LLC →**

Jul 10, 2024, 10:00 ET

---

PHILADELPHIA, July 10, 2024 /PRNewswire/ --

**NastLaw LLC announces: If you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019, your rights may be affected by a proposed class action settlement.**

*A federal court authorized this notice. This is not a solicitation from a lawyer.*

**What is the lawsuit about?** A proposed Settlement has been reached in a class action lawsuit ("the Lawsuit"), which alleges that Sandoz Inc. and Fougera Pharmaceuticals Inc. (collectively "Settling Defendants") and other generic drug manufacturers violated the federal antitrust laws by conspiring to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs (the "Named Generic Drugs"), causing direct purchasers of the Named Generic Drugs to pay more than they should have. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. The proposed Settlement does not resolve any of the claims of the Settlement Class against the remaining Defendants. The Lawsuit against the remaining Defendants is ongoing.

**Who is included?** The Court has certified a Settlement Class that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the Named Generic Drugs from one or more Current or Former Defendants in the United States and its territories and possessions, at any time<sup>oo</sup>

during the period from May 1, 2009 through December 31, 2019. Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities. The Settlement Agreement listing the Named Generic Drugs and Current and Former Defendants is available on the Settlement website: [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com). The Settlement Agreement also is on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106 in the case *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 2:16-MD-02724.

**What does the settlement provide?** The proposed Settlement provides for a \$265,000,000.00 payment by Settling Defendants ("Settlement Fund"). The Settlement Fund may be reduced to \$233,200,000.00 or increased to a maximum of \$327,351,850.00 under certain circumstances as explained in the Settlement Agreement. In addition, the Direct Purchaser Plaintiff ("DPP") attorneys who have worked on the Lawsuit for the Settlement Classes will seek Court approval to pay expenses, and service awards for the class representatives (or named plaintiffs) out of the Settlement Fund. DPP attorneys will also request attorneys' fees of up to one-third of the net Settlement Fund, including interest, after expenses (and service awards) are deducted, and any portions of the Settlement Funds created from DPPs' prior Settlements that have been set aside pursuant to Court Order. Any motion for fees, expenses and service awards will be posted on the Settlement website [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com), no later than November 22, 2024. The calculations of the dollar amount that each Settlement Class Member will be paid from the Settlement Fund are set forth in the Plan of Allocation, which also is available on [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com).

**What are your options?** If you are a Settlement Class Member and you do nothing, you will remain in the Settlement Class and are eligible to participate in the Settlement as described in this notice, if the Settlement is approved. However, you will need to complete, sign, and return the claim form (once it is sent to you) in order to obtain a payment. We do not know when the claim forms will be mailed. You should check [GenericDrugsDirectPurchaserSettlement.com](http://GenericDrugsDirectPurchaserSettlement.com) for information regarding timing. If you *did not* receive a Notice in the mail, and you think you are a potential Settlement Class Member, please identify yourself or your company by letter to the following address: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217. Or send an email to [info@GenericDrugsDirectPurchaserSettlement.com](mailto:info@GenericDrugsDirectPurchaserSettlement.com), or call 877-315-0583. You may be required to submit proof of a qualifying direct purchase to establish that you are a Settlement Class

Member. Such claimants may also be required to submit purchase data as part of the claims process. As a Settlement Class Member, unless you opt out of the Settlement, you will be bound by all orders and judgments of the Court.

In addition, if you are a Settlement Class Member, you may request exclusion from (or opt out of) the Settlement, and if you do not opt out, you may also object to the Settlement. Instructions for opting-out or objecting can be found in the publicly available case file and website, as described above. You must mail your request to opt out or your objection by October 8, 2024. The Court will hold a Fairness Hearing on March 17, 2025, to decide whether to approve the Settlement and any requests for fees, expenses, and service awards for the Class Representatives. The Court will also consider a Plan of Allocation for distributing the Settlement Fund to Settlement Class Members. If there are objections, the Court will consider them at the hearing. You do not need to attend the hearing. If you wish to appear at the hearing, you must file a "Notice of Intention to Appear" with the Court and you may hire your own attorney to appear in Court for you at your own expense.

**For more information:** Go to the website: [GenericDrugsDirectPurchaserSettlement.com](https://GenericDrugsDirectPurchaserSettlement.com) or call 877-315-0583 for more information on the Settlement, the lawsuit, and your potential rights and options related to the Settlement, and the Plan of Allocation. The website includes, for example, a list of the generic drugs that you would have had to purchase and a list of the generic manufacturers that you would have had to purchase **directly** from in order to be eligible for a payment.

SOURCE Nast Law LLC

# EXHIBIT E

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

1. Accredo Health Group, Inc.
2. Acme Markets
3. Advanced PCS
4. AdvanceRx Com Inc
5. Albany Area Primary Health Care, Inc.
6. Albertsons
7. Albertsons Companies LLC
8. Albertsons Companies, Inc.
9. Albertsons LLC
10. Albertsons Market
11. Albertson's, Inc.
12. Alliance
13. Alliance BMP
14. Alliance Boots
15. Alliance Healthcare
16. Alliance RX Walgreens Prime Pharmacy
17. Alliance Sante
18. Alliance UniChem
19. Allina Health System
20. American Drug Stores
21. American Stores Company
22. Andronico's
23. Andronico's Community Markets
24. Armstrong County Memorial Hospital, d/b/a ACMH Hospital
25. Astera Health, f/k/a Tri-County Health Care
26. Augusta Health Care, Inc., d/b/a Augusta Health
27. Avera Health
28. Baker's
29. Balducci's Food Lover's Markets
30. Baptist Health
31. Bartell Drug Company
32. Baxter County Hospital, Inc.; d/b/a Baxter Regional Medical Center
33. Baystate Health, Inc.
34. Beaufort Jasper Hampton Comprehensive Health Services, Inc.
35. Berkshire Health Systems, Inc.
36. Billings Clinic
37. Bi-Lo
38. Bi-Lo Holding Finance LLC
39. Bi-Lo Holding LLC
40. Bi-Lo LLC
41. Bi-Lo, LLC

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

42. Bowen Development
43. Bravo Health Mid-Atlantic Inc.
44. Bravo Health Pennsylvania Inc.
45. Broad Top Area Medical Centers, Inc.
46. Bruno's Supermarkets Incorporated
47. Burlington Drug
48. Burlington Drug Company
49. Burrells
50. Burrells Limited
51. Cape Cod Healthcare, Inc.
52. Care New England Health System, d/b/a Care New England
53. CaroMont Health System
54. Carr-Gottstein Foods Co.
55. CenterWell Pharmacy, Inc.
56. CentraCare Health System
57. Central Market
58. Central Texas Community Health Centers, d/b/a CommUnityCare
59. Cigna Corporation
60. Cigna Health and Life Insurance Company
61. Cigna HealthCare of Arizona, Inc.
62. Cigna HealthCare of California, Inc.
63. Cigna HealthCare of Colorado, Inc.
64. Cigna HealthCare of Connecticut, Inc.
65. Cigna HealthCare of Florida, Inc.
66. Cigna HealthCare of Georgia, Inc.
67. Cigna HealthCare of Illinois, Inc.
68. Cigna HealthCare of Indiana, Inc.
69. Cigna HealthCare of Maine, Inc.
70. Cigna HealthCare of Massachusetts, Inc.
71. Cigna HealthCare of Mid-Atlantic, Inc.
72. Cigna HealthCare of New Hampshire, Inc.
73. Cigna HealthCare of New Jersey, Inc.
74. Cigna HealthCare of North Carolina, Inc.
75. Cigna HealthCare of Pennsylvania, Inc.
76. Cigna HealthCare of South Carolina, Inc.
77. Cigna HealthCare of St. Louis, Inc.
78. Cigna HealthCare of Tennessee, Inc.
79. Cigna HealthCare of Texas, Inc.
80. Cigna HealthCare of Utah, Inc.
81. City Market
82. Collier Health Services, Inc., d/b/a Healthcare Network

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

83. Community Health Center of Snohomish
84. Company Amigos United
85. Confluence Health
86. Conway Regional Health System
87. Cook County Hospital District, d/b/a North Shore Health
88. Cook Hospital
89. Copps Food Center
90. Crusaders Central Clinic Association
91. CuraScript, Inc.
92. CVS Health Corp.
93. CVS Pharmacy, Inc.
94. Cystic Fibrosis Services
95. Cystic Fibrosis Services Inc.
96. Cystic Fibrosis Services LLC
97. Dallas County Medical Center
98. Delta Memorial Hospital
99. Dillon
100. Dillon Companies, Inc.
101. Dominick's
102. Dominick's Finer Foods, LLC
103. Douglas County Hospital, d/b/a Alomere Health
104. Drew Memorial Hospital, Inc., d/b/a Drew Memorial Health System
105. Duane Reade
106. Duane Reade, Inc.
107. Duval's Pharmacy, Inc.
108. East Boston Neighborhood Health Center Corporation
109. Eckerd
110. Ely-Bloomenson Community Hospital
111. Erie Family Health Center, Inc.
112. ESI Mail Pharmacy Service, Inc.
113. Essentia Health
114. Evangelical Community Health
115. Express Scripts Holding Company
116. Express Scripts Pharmaceutical Procurement LLC
117. Express Scripts Pharmacy, Inc.
118. Express Scripts, Inc.
119. Extreme Value
120. Extreme Value Centers
121. Fairview Health Services
122. FMJ, Inc.
123. Food 4 Less



*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

124. Food 4 Less Holdings, Inc.
125. Foods Pavilion
126. Fred Meyer
127. Fred Meyer Jewelers, Inc.
128. Fred Meyer Stores, Inc.
129. Fred Meyer, Inc.
130. Fresco Y Mas
131. Fry's
132. Fulton county Medical Center
133. Genuardi's
134. Genuardi's Family Markets LP
135. Gerbes
136. Gillette Children's Specialty Healthcare
137. Glacial Ridge Health System
138. Globe Stores
139. Granby Pharmacy, Inc., d/b/a Center Pharmacy
140. Great Lakes Bay Health Centers
141. Great Salt Plains Health Center, Inc.
142. Greater Lawrence Family Health Center
143. Green Hills Insurance
144. H.E. Butt Grocery Company
145. H.E. Butt Grocery Company L.P.
146. Haggen
147. Haggen Food & Pharmacy
148. Happy Harry's
149. Happy Harry's Discount Drug Stores, Inc.
150. Happy Harry's Inc.
151. Harris Teeter
152. Harris Teeter, Inc.
153. Harris Teeter, LLC
154. Harveys
155. Health Partners of Western Ohio
156. HealthPoint
157. HealthSpring Life & Health Insurance Company, Inc.
158. HealthSpring of Florida, Inc.
159. HealthSpring Pharmacy of Tennessee, LLC
160. HealthSpring Pharmacy Services, LLC
161. Healthy Options, Inc.
162. H-E-B
163. Hennepin Healthcare System, Inc.
164. Home Chef

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

165. Humana Inc.
166. Humana Pharmacy, Inc.
167. Independence Health System
168. Infinity Infusion
169. Innoviant Pharmacy Inc.
170. Intermountain Health Care, Inc.
171. International Community Health Services
172. J M Smith
173. J M Smith Corporation
174. J.H. Harvey Co., LLC
175. Jackson-Madison County General Hospital District, d/b/a West Tennessee Healthcare
176. Jay C Food Stores
177. Jerseymaid Milk Products
178. Jewel Food Stores
179. Jewel Foods
180. Jewel Foods, Inc.
181. Jewel-Osco Pharmacy
182. Junior Food Stores of West Florida, Inc.
183. Kerr Drug
184. Kessel
185. Kessel Food Markets, Inc.
186. King Soopers
187. Kings Food Markets
188. Kiosk Medicine Kentucky, LLC
189. Kittson Healthcare
190. Knight Health Holdings LLC, d/b/a ScionHealth
191. Kootenai Hospital District
192. KRGP Inc.
193. Kroger
194. Kroger Limited Partnership I
195. Kroger Limited Partnership II
196. Kroger Texas L.P.
197. Lake Region Healthcare Corporation
198. Lakewood Health System
199. Lawrence Brothers
200. Lawrence Brothers Co.
201. Lawrence Brothers Pharmacy
202. Lehigh Valley Health Network, Inc.
203. LifeCare Medical Center
204. Lifepoint Corporate Services, General Partnership

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

205. Lifespan Corporation
206. Logan Health
207. Longview Wellness Center, Inc., d/b/a Wellness Pointe
208. Lucerne Foods, Inc.
209. Lucky Stores (Utah locations)
210. Lutheran Charity Association, d/b/a Jamestown Regional Medical Center
211. Lynnfield Compounding Center, Inc.
212. Lynnfield Drug, Inc.
213. Madelia Health
214. Madison Health, f/k/a Madison Memorial Hospital
215. Madison Healthcare Services, d/b/a Madison Hospital
216. Main Line Health, Inc.
217. Marana Health Center, Inc.
218. Mariano's Fresh Market
219. Market Street
220. Mary Ruan Hospital d/b/a Mary Rutan Health
221. Mass General Brigham Incorporated
222. Matthews Property 1, LLC
223. Mayo Clinic
224. May's Drug Stores
225. May's Drug Stores, Inc.
226. Medco Containment Insurance Company of NY
227. Medco Containment Life Insurance Company
228. MedCura Health, Inc.
229. Medicenter
230. Med-X
231. Med-X Corporation
232. Meeker Memorial Hospital and Clinics
233. Memorial Hospital of Laramie County, d/b/a Cheyenne Regional Medical Center
234. Memorial Hospital of Sweetwater County
235. Memorial Sloan Kettering Cancer Center
236. Metro Market
237. Middlesex Health System, Inc., d/b/a Middlesex Health
238. Millcreek Community Hospital
239. Mille Lacs Health System
240. Montefiore Medical Center
241. Mount Nittany Health System
242. Mount Sinai Hospitals Group, Inc.
243. Murray County Medical Center
244. MVMEDSHOP, Inc., d/b/a Vineyard Scripts
245. Nationwide Children's Hospital

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

246. New Albertson's Inc.
247. New Albertsons L.P.
248. North Big Horn Hospital District
249. North Canyon Medical Center
250. North Memorial Health Care, d/b/a North Memorial Health
251. North Olympic Healthcare Network
252. Northern Itasca Hospital District, d/b/a Bigfork Valley
253. Northfield Hospitals + Clinics
254. Novant Health, Inc.
255. Nuvance Health
256. NYU Langone Hospitals
257. Ochsner Clinic Foundation
258. Olmsted Medical Center
259. Omnicare
260. OptumRx Group Holdings, Inc.
261. OptumRx Holdings, LLC
262. OptumRx, Inc.
263. Ortonville Area Health Services
264. Osco Drugs
265. Overlake Hospital Medical Center
266. Owen's
267. Owen's Supermarket
268. Pak 'N Sav
269. Paul's Market
270. Pavilions Place Randall's
271. Pay Less Super Markets
272. PeaceHealth
273. Peak Vista Community Health Centers
274. Penn Highlands Healthcare
275. Perham Hospital District, d/b/a Perham Health
276. Peyton's
277. Peyton's Fountain
278. Peyton's Mid-South Company
279. Peyton's Northern
280. Peyton's Pheonix
281. Peyton's-Southeastern, Inc.
282. Pick 'n Save
283. Pikeville Medical Center, Inc.
284. Postal Prescription Services
285. Prime Therapeutics Specialty Pharmacy
286. Prime Therapeutics Specialty Pharmacy LLC

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

287. Priority Healthcare Corporation
288. Priority Healthcare Distribution, Inc.
289. Providence St. Joseph Health
290. Pueblo Community Health Center, Inc.
291. QFC
292. Raley's of New Mexico
293. Ralphs
294. Ralphs Grocery Company
295. Randall's Food & Drugs LP
296. Regional Health Services, d/b/a Glencoe Regional Health
297. Ridgeview Medical Center, Inc., d/b/a Ridgeview
298. Rite Aid Corporation
299. Rite Aid Hdqtrs. Corp.
300. River's Edge Hospital
301. Riverview Healthcare Association
302. Riviera Brands
303. Roanoke Chowan Community Health Center
304. Roundy's Inc.
305. Ruler Foods
306. Rutherford County Primary Care Clinics, Inc., d/b/a Primary Care & Hope Clinic
307. RWJ Barnabas Health, Inc.
308. S & W Pharmacy, Inc.
309. S&W Pharmacy
310. Safeway
311. Safeway Food & Drug
312. Safeway Inc.
313. Salem Community Hospital, d/b/a Salem Regional Medical Center
314. Sam's Club
315. Samson Merger Sub, LLC
316. Sanford
317. Save-Rite
318. Sav-On Drug
319. Scott's Foods
320. Scott's Pharmacy
321. Select Medical Corporation
322. SGOH Acquisition, Inc., d/b/a Ozarks Community Hospital
323. Shands Jacksonville Medical Center, Inc.
324. Shands Teaching Hospital and Clinics, Inc.
325. Shasta Community Health Center
326. Shawnee Health Service and Development Corporation
327. Shaw's Supermarkets, Inc.

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

- 328. Shop-Rite, LLC
- 329. Simon David
- 330. Sleepy Eye Medical Center
- 331. Smith Drug
- 332. Smith Drug Company
- 333. Smith's
- 334. Smith's Food & Drug Centers, Inc.
- 335. Southeastern Grocers Inc.
- 336. Southeastern Grocers LLC
- 337. Specialty Products Acquisitions, LLC
- 338. St. Clair Health Corp., d/b/a St. Clair Health
- 339. St. Luke's Health Network, Inc., d/b/a St. Luke's University Health Network
- 340. St. Luke's Health System, Ltd.
- 341. St. Luke's Hospital of Duluth
- 342. St. Thomas Community Health Center
- 343. Stamford Health, Inc.
- 344. Star Market
- 345. Stigler Health & Wellness Center, Inc.
- 346. Sunrise R&D Holdings, LLC
- 347. Sunrise Technology LLC
- 348. Super D. Drugs Acquisition Co.
- 349. Super Saver Foods
- 350. Superbrand
- 351. Superior
- 352. Superior Acquisitions Limited
- 353. Superior Holdings Limited
- 354. Sweet Bay
- 355. Syringa Hospital Districts, d/b/a Syringa Hospital & Clinics
- 356. Tel-Drug of Pennsylvania, LLC
- 357. Tel-Drug, Inc.
- 358. The Chautauqua Center, Inc.
- 359. The Children's Hospital Corporation, d/b/a Boston Children's Hospital
- 360. The Children's Hospital of Philadelphia
- 361. The Cigna Group
- 362. The DCH Health Care Authority, d/b/a DCH Health System
- 363. The Guthrie Clinic
- 364. The Kroger Co
- 365. The Kroger Co. of Michigan
- 366. The New York and Presbyterian Hospital
- 367. The Regents of the University of Michigan on behalf of University of Michigan Health

*In re: Generic Pharmaceuticals Pricing Antitrust Litigation,*  
Case No: 2:16-MD-02724 (E.D. Pa.)

**Timely Exclusion Requests – Sandoz Settlement**

- 368. The Vons Companies, Inc.
- 369. Thomas Jefferson University, d/b/a Jefferson Health
- 370. TLC Corporate Services LLC
- 371. Tom Thumb Food & Drugs
- 372. Tri-Area Community Health
- 373. Trinity Home Care
- 374. UC Health, LLC, d/b/a UC Health
- 375. UHS of Delaware, Inc.
- 376. UMass Memorial Care, Inc.
- 377. United Express
- 378. United HealthCare Services, Inc.
- 379. United Hospital District
- 380. United Supermarkets
- 381. United Supermarkets, LLC
- 382. University Health Systems of Eastern Carolina, d/b/a ECU Health
- 383. Upham's Corner Health Committee, Inc., d/b/a Upham's Corner Health Center
- 384. UPMC
- 385. USA Drug
- 386. USA/Super D Franchising
- 387. Valley Health System
- 388. Valor Health
- 389. Vons
- 390. Vons Grocery Company
- 391. WakeMed d/b/a WakeMed Health & Hospitals
- 392. Walgreen
- 393. Walgreen Co.
- 394. Walgreen Company
- 395. Walgreens
- 396. Walmart Inc.
- 397. Welia Health
- 398. Wellpath LLC
- 399. White River Health System, Inc., d/b/a White River Medical Center
- 400. Winn-Dixie Corporation
- 401. Winn-Dixie Logistics, Inc.
- 402. Winn-Dixie Procurement, Inc.
- 403. Winn-Dixie Stores, Inc.
- 404. Winona Health Services